ABCL 635
Alternative Names: ABCL-635Latest Information Update: 13 Aug 2024
At a glance
- Originator Abcellera
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Endocrine disorders; Metabolic disorders
Most Recent Events
- 06 Aug 2024 AbCellera announces intention to submit Clinical Trial Application for Endocrine and Metabolic disorders in second quarter of 2025 (AbCellera pipeline, January 2024)
- 24 Jan 2024 AbCellera plans a clinical trial for Metabolic and endocrine disorder in 2025
- 17 Jan 2024 ABCL 635 is available for licensing as of 17 Jan 2024 (AbCellera website, January 2024)